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Thrombin activatable ﬁbrinolysis inhibitor and the risk for deep vein thrombosis
Nico H. van Tilburg, Frits R. Rosendaal, and Rogier M. Bertina
Thrombin activatable ﬁbrinolysis inhibi-
tor (TAFI, or procarboxypeptidase B) is
the precursor of a recently described
carboxypeptidase that potently attenu-
ates ﬁbrinolysis. Therefore, we hypoth-
esized that elevated plasma TAFI levels
induce a hypoﬁbrinolytic state associ-
ated with an increased risk for venous
thrombosis. To evaluate this hypothesis,
we developed an electroimmunoassay
for TAFI antigen and used this assay to
measure TAFI levels in the Leiden Throm-
bophilia Study, a case–control study of
venous thrombosis in 474 patients with a
ﬁrst deep vein thrombosis and 474 age-
and sex-matched control subjects. In 474
healthy control subjects, an increase of
TAFI with age was observed in women but
not in men. Oral contraceptive use also
increased the TAFI concentration. TAFI
levels above the 90th percentile of the
controls (G 122 U/dL) increased the risk
for thrombosis nearly 2-fold compared
with TAFI levels below the 90th percentile
(odds ratio, 1.7; 95% conﬁdence interval,
1.1-2.5). Adjustment for various possible
confounders did not materially affect this
estimate. These results indicate that ele-
vated TAFI levels form a mild risk factor
for venous thrombosis. Such levels were
found in 9% of healthy controls and in
14% of patients with a ﬁrst deep vein
thrombosis. Elevated TAFI levels did not
enhance the thrombotic risk associated
with factor V Leiden but may interact with
high factor VIII levels. (Blood. 2000;95:
2855-2859)
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Introduction
During normal hemostasis there is a balance between coagulation
and ﬁbrinolysis. Disturbances of this balance may result in a
bleeding disorder or in a thrombotic tendency. Activated protein C
(APC), the endproduct of the protein C anticoagulant pathway,1,2
plays an important role in maintaining this balance through its
anticoagulant3,4 and proﬁbrinolytic5-8 properties. In fact, part of its
proﬁbrinolytic action was found to be related to its anticoagulant
properties, and the existence of a plasma component was proposed
that, on activation by thrombin, would act as an inhibitor of
t-PA–dependent ﬁbrinolysis.9 Bajzar et al10 have isolated this
protein, the thrombin activatable ﬁbrinolysis inhibitor (TAFI). It
appeared to be identical to plasma procarboxypeptidase B11 and
procarboxypeptidase U.12
Detailed biochemical studies revealed that TAFI can be con-
verted to an active carboxypeptidase by enzymes such as tryp-
sin, thrombin, and plasmin.10,11 Activation of TAFI by thrombin
is increased more than 1000-fold in the presence of its cofactor
thrombomodulin.13,14After activation,TAFI suppresses ﬁbrinolysis
through the removal of carboxy terminal lysine residues that appear
during proteolysis of the ﬁbrin polymers and that serve an
important role in assembling the components of the ﬁbrinolytic
system on the ﬁbrin surface.15,16 Together these properties of TAFI
make it an important negative regulator of ﬁbrino-
lytic efficiency in vitro.17 Therefore, we hypothesized that high-
plasma TAFI levels are a risk factor for venous thrombosis. To test
this hypothesis we made use of a large population-based case–
control study on venous thrombosis, the Leiden Thrombophilia
Study (LETS).18,19
Materials and methods
Puriﬁcation of TAFI
Fresh frozen plasma (acid citrate dextrose anticoagulant) was thawed and
adsorbed with 2% (wt/vol) aluminum hydroxide suspension for 20 minutes
at room temperature. After centrifugation 500 mL adsorbed plasma was
passed through a lysine–Sepharose column (40 mL bed volume) equili-
brated in 50 mmol/L triethanolamine and 100 mmol/L NaCl, pH 7.4
(TEA–NaCl). The column was washed with the same buffer until the A280
was less than 0.1 The wash procedure was continued with 300 mL
TEA–NaCl buffer. This wash, which contained approximately 100 U TAFI,
was passed through a glu–plasminogen–Sepharose column, equilibrated in
TEA–NaCl (20 mL bed volume). The column was washed with 2 vol
TEA–NaCl. A 0- to 200-mmol/L linear gradient of e-amino-n-caproic acid
(e-ACA) in TEA–NaCl was applied, and TAFI was eluted at approximately
35 mmol/Le-ACA.TheseTAFI-containing fractions were stored at 220°C.
The ﬁnal yield of TAFI was approximately 10%.
After SDS-PAGE puriﬁed TAFI shows a single band of 60 kd.
SDS-PAGE was performed under nonreducing conditions, using the Fast
System (Amersham Pharmacia Biotech, Uppsala, Sweden) and a 5% to
15% gradient gel. Protein bands were visualized by silver staining. The
concentration of isolated TAFI was calculated from the absorbance at 280
nm (after correction for the absorbance at 320 nm) using a molar absorption
coefficient of 1.28 3 105 mol/L21cm21 (see 10).
Preparation of TAFI-deﬁcient plasma
Rabbits were immunized with isolated human TAFI using standard
procedures. IgG was isolated from the antiserum with protein-A Sepharose
4B and coupled to CNBr-activated Sepharose-4B (Amersham Pharmacia
Biotech) as described by the manufacturer. Citrated plasma was passed over
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fractions were tested for the presence of TAFI with an electroimmunoassay
using rabbit polyclonal antibodies against TAFI. TAFI-deﬁcient fractions
(less than 1.6 U/dL) were pooled and frozen at 220°C.
Preparation of speciﬁc polyclonal anti-TAFI antibodies
The crude rabbit anti-TAFI serum was tested in crossed immunoelectropho-
resis. Pooled normal plasma showed 1 major precipitation arc with some
minor contaminations. To remove these contaminating antibodies, the
antiserum was mixed with one-tenth volTAFI deﬁcient plasma (prepared as
described above), stored overnight at 4°C, heated at 56°C for 30 minutes,
and centrifuged (10 000g, 10 minutes, 4°C). IgG was isolated using protein
A–Sepharose-4B and stored in TEA–NaCl, at 220°C at a concentration of
6 mg/mL.
Glu–plasminogen–Sepharose
Glu-plasminogen was isolated by affinity chromatography on lysine–
Sepharose as described previously20 and coupled to CNBr-activated
Sepharose (0.25 mg/mL) according to the instructions of the manufacturer.
Electroimmunoassay
Electroimmunoassaywascarriedoutfollowingstandardprocedures.Briefly,
a suitable percentage (0.5% vol/vol) of anti-TAFI IgG was added to 1.0%
agarose (SeaKem LE, cat. No. 50 004; FMC BioProducts, Rockland, ME)
in 31.6 mmol/Ltricine, 91.5 mmol/LTrizma base, 1 mmol/LEDTA, pH 8.8.
TAFI standards were prepared by dilution of puriﬁed TAFI in TAFI-
deﬁcient plasma. These standards (20.5 to 164 U/dL) had been calibrated
against pooled normal plasma. Standards and undiluted 5-µL samples were
applied in wells 2.5 mm in diameter. Plates were electrophoresed at 2 to 3
V/cm for 18 hours at 10°C to 15°C.After drying and staining, the length of
the precipitation peak was measured and the amount ofTAFI was calculated
by intrapolation on the standard curve as the mean of duplicate tests. Serial
dilutions of isolated TAFI (0 to 95 nmol/L) in buffer, TAFI-deﬁcient
plasma, or plasminogen- and TAFI-deﬁcient plasma gave identical precipi-
tation peaks in the Laurell assay. From these data it could be calculated that
with the Laurell assay we recovered 100% of the TAFI, which was added to
the deﬁcient plasmas. The same recovery was obtained when different
amounts of puriﬁed TAFI were added to pooled normal plasma.
Measurement of TAFI antigen in plasma
Using the electroimmunoassay, no TAFI (less than 1.6 U/dL) was detected
in TAFI-depleted plasma, prepared by immuno-depletion with a monoclo-
nal antibody against TAFI (Nik-9H10; see Mosnier et al27). At a TAFI
antigen level of approximately 100 U/dL, the intra-assay and inter-assay
coefficients of variation were 6% (n 5 20) and 6% (n 5 107), respectively.
In the 64 healthy control subjects who contributed to the pooled normal
plasma, the mean TAFI level was 100 U/dL (SD, 9 U/dL; range, 53 to 139
U/dL).
Pooled normal plasma
Blood was collected by venipuncture in plastic tubes containing one-tenth
vol 0.106 mol/L trisodium citrate. The blood was centrifuged at 2000g for
20 minutes at 20°C. The platelet-poor plasma of 64 healthy volunteers
(women on oral contraceptives were excluded) was pooled and stored at
270°C in aliquots of 0.5 mL. This pooled normal plasma was considered to
contain 100 U/dL TAFI; in this pooled normal plasma, 100 U/dL TAFI
corresponded with 106 nmol/L TAFI or 6.4 g/mL TAFI (using a molecular
weight of 60 000).
Leiden thrombophilia study
The design of this population-based case–control study (LETS) has been
described in detail.18 Brieﬂy, consecutive patients with an objectively
diagnosed ﬁrst episode of deep vein thrombosis were selected from the ﬁles
of 3 anticoagulation clinics in The Netherlands. All patients were younger
than 70 years and were not diagnosed with malignant disorders. Control
subjects were acquaintances of patients or partners of other patients,
matched for age and sex with the patients. The study included 474 patients
and 474 control subjects. Blood was collected into 0.1 vol of 0.106 mol/L
trisodium citrate. Plasma was prepared by centrifugation for 10 minutes at
2000g at room temperature and was stored at 270°C.
Statistical analysis
Determinants of TAFI were investigated by linear regression. Odds ratios
(ORs) were calculated as estimates of relative risk for thrombosis in the
unmatched fashion adjusted for age and sex and possible confounders by
logistic regression; 95% conﬁdence intervals (95% CI) were constructed
according to Woolf21 or were derived from the model estimates.
Results
TAFI antigen levels
The mean TAFI antigen concentration in all 948 patients and
controls was 107 (6 13 SD) U/dL. TAFI antigen levels were
normally distributed. Mean TAFI levels were similar in patients
(mean, 107 U/dL; SD, 6 14) and control subjects (mean, 107
U/dL; SD 6 12), but there were more patients than controls with
high TAFI levels; 14% of patients had levels exceeding the 90th
percentile compared with 9% in control subjects.
Determinants of TAFI were studied in the healthy control
subjects. There was no difference in the mean TAFI levels in men
(mean, 107 U/dL; SD 6 13) and women (mean, 106 U/dL; SD
612). Univariate analysis by linear regression showed an increase
of TAFI concentration of 0.11 U/dL per year (95% CI, 0.03 to
0.19). In men TAFI levels were not affected by age (0.06 U/dL per
year; 95% CI, 20.08 to 0.20), whereas in women the TAFI
concentration increased (0.14 U/dLper year; 95% CI, 0.03 to 0.25).
TAFI concentrations in women using oral contraceptives were
slightly higher than in women not using them (111 U/dL; 95% CI,
108 to 114 and 105 U/dL; 95% CI, 103 to 106, respectively).After
correction for the effect of oral contraceptive use (at the time of
blood collection), the effect of age on TAFI concentration in
women became even more pronounced (0.28 U/dL per year; 95%
CI, 0.17 to 0.39).
TAFI concentration and the risk for venous thrombosis
Table 1 shows stratiﬁcation into 2 groups of the TAFI levels of
patients and control subjects, above and below the 90th percentile
(as observed in control subjects). Crude odds ratios were calculated
for patients with TAFI concentrations above the 90th percentile,
with the group below the 90th percentile as the reference category.
Higher TAFI concentrations (more than 122 U/dL) were associated
with an increased risk for thrombosis (OR, 1.7; 95% CI, 1.1 to 2.5).
The age- and sex-adjusted odds ratio was 1.7 (95% CI, 1.1 to 2.5).
In men, TAFI levels exceeding 122 U/dL were associated with an
odds ratio of 1.3 (95% CI, 0.7 to 2.5), whereas in women the odds
ratio was 2.0 (95% CI, 1.1 to 3.4). An additional increase in the
cutoff point to the 95th or 99th percentile did not result in a further
increase of the odds ratios (OR, 1.5; 95% CI, 0.8 to 2.7 and OR,
2.0; 95% CI, 0.5 to 8.1, respectively).
Table 2 shows patients and control subjects stratiﬁed into 5
groups according to the TAFI concentration in the controls. Crude
odds ratios were calculated using the lowest quintile as the
Table 1. Thrombosis risk for TAFI antigen
TAFIAntigen (U/dL) Patients n (%) Controls n (%) OR 95% CI
,123 408 (86) 432 (91) 1*
.122 (P90) 66 (14) 42 (9) 1.7 1.1-2.5
*Reference category.
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TAFI concentrations over these quintiles.
Oral contraceptive use is associated with an increased risk for
venous thrombosis.22,23 Hence, we adjusted for oral contraceptive
use (either at the time of thrombosis or at the time of blood
collection) by logistic regression analysis. This resulted only in
mild changes in the odds ratio for levels exceeding the 90th
percentile (OR, 1.9; 95% CI, 1.1 to 3.3 and OR, 2.3; 95% CI, 1.3 to
4.1, respectively).
Association of TAFI with other coagulation factors
Univariate regression analysis demonstrated that in the controls
(n 5 474)TAFI levels were dependent on several other coagulation
factors tested. Table 3 summarizes the parameters of the regression
lines that deﬁne the relation between TAFI levels and the levels of
other clotting factors. When the inﬂuence of the concentration of
the same coagulation proteins on the TAFI level was analyzed in
multiple regression, ﬁbrinogen and antithrombin disappeared as
independent variables. Therefore, it is not surprising that compared
with persons with TAFI levels lower than the 90th percentile, those
with TAFI levels higher than the 90th percentile also have elevated
levels of protein C and factor II (Table 4).
When we adjusted for all factors associated with TAFI levels
(sex, age, use of oral contraceptives, ﬁbrinogen, antithrombin,
protein C, and factor II levels, excluding persons using oral anticoagu-
lant drugs), there remained an increased risk for thrombosis in persons
whoseTAFI levels exceeded the 90th percentile (OR, 1.5).
Elevated TAFI and other common risk factors for thrombosis
Tables 5 and 6 summarize the effect of elevated TAFI levels
(greater than 90th percentile) on the risk for thrombosis of factor V
Leiden and elevated factor VIII (more than 150 IU/dL). There are
no indications that an elevatedTAFI level will enhance the effect of
factor V Leiden on risk for thrombosis,24 whereas there may be
some synergy with high levels of factor VIII with regard to risk for
thrombosis.
Discussion
TAFI (or procarboxypeptidase B) is a plasma zymogen that, when
converted to an enzyme, potently inhibits ﬁbrinolysis.11,17 This
indicates that increased levels of TAFI may be associated with an
increased risk for thrombosis.25,26 To investigate this, we measured
TAFI antigen levels in patients and control subjects of the Leiden
Thrombophilia Study. In the ﬁrst part of this study, we analyzed the
effects of sex, age, and oral contraceptive use onTAFI levels. In the
second part, we studied the possibility of an association of
increased TAFI concentrations and thrombosis.
No difference in TAFI concentration was found between men
and women. Analysis of the effect of age showed no increase of
TAFI concentration in men and an age-dependent increase in
women. The latter effect was partially masked by the use of oral
contraceptives. Recently Schatteman et al25 reported an effect of
age on TAFI levels in men, using a 2-stage functional assay for
procarboxypeptidase U (or TAFI).
Stratiﬁcation of patients and control subjects, with the 90th
percentile in the controls as the cutoff, resulted in a mildly increased
oddsratio(1.7)forthosewithTAFIlevelsgreaterthan122U/dL.Useof
the 95th and 99th percentiles did not result in a further increase of the
odds ratio.There is no support for a gradual relationship between mildly
increased TAFI levels and the risk for thrombosis (Table 2). After
adjustment for age, elevated TAFI antigen level remained a risk factor
for thrombosis. Adjustment for oral contraceptive use during blood
collection did not affect the association between TAFI and the risk for
thrombosis. Further, elevated TAFI levels did not enhance the risk for
thrombosis associated with factor V Leiden but may have interacted
with high factorVIII levels (Tables 5 and 6).
In this study we used the TAFI antigen as a measure of plasma
TAFI concentration. Recently Mosnier et al27 and Schatteman et
al
25 reported methods for the measurement of TAFI activity in
plasma. Mosnier et al27 found a linear relationship between TAFI
activity and TAFI antigen in plasma in 20 healthy control subjects.
Therefore, we may conclude that there is no indication for the
common presence of molecular variants of TAFI with enhanced
speciﬁc activity in the general population.
The molecular basis of elevated TAFI levels is not yet clear.
There are no known polymorphisms in the TAFI gene that are
associated with plasma TAFI. Recently, Zhao et al28 described 2
isoforms of TAFI. Detailed functional studies of the recombinant
proteins did not reveal a difference between the 2 proteins (TAFI
Ala 147 and TAFI Thr 147). The authors proposed to investigate
the isoform distribution in healthy volunteers and patients with
thrombotic disorders. A recent report26 on the characterization of
Table 2. Thrombosis risk for TAFI antigen
TAFIAntigen (U/dL) Patients n (%) Controls n (%) OR 95% CI
, 96 94 (20) 86 (18) 1*
96-103 105 (22) 98 (21) 1 0.7-1.5
104-109 86 (18) 94 (20) 0.8 0.6-1.3
110-116 74 (16) 96 (20) 0.7 0.5-1.1
. 116 115 (24) 100 (21) 1.1 0.7-1.6
*Reference category.
Table 3. Association of TAFI and other coagulation factors
Factor b* 95% CI
Fibrinogen (g/L) 3.04 1.36-4.72
Antithrombin (U/dL) 0.20 0.09-0.30
Protein C (U/dL) 0.21 0.15-0.27
Prothrombin (U/dL) 0.23 0.16-0.30
*Regression coefficient b shows the increase of TAFI (U/dL) per U/dL or g/L
increase of the coagulation factor studied.
Table 4. Levels of other coagulation factors in persons with elevated
TAFI levels
Factor
TAFI , P90*
n 5 432 (431†)
TAFI . P90*
n 5 42
Fibrinogen (g/L) 3.24 (0.64) 3.50 (0.83)
Antithrombin (U/dL) 99.0 (10.4) 99.9 (10.5)
Protein C (U/dL)† 101.0 (17.7) 116.2 (17.9)
Prothrombin (U/dL)† 102.9 (14.6) 112.1 (13.7)
*Mean (6SD) levels of coagulation proteins in persons with TAFI levels ,P90
and .P90.
†Number of persons for analysis of protein C and prothrombin, i.e. not using oral
anticoagulants.
Table 5. Elevated TAFI and factor V Leiden
TAFI
FV
Leiden
Patients
(n)
Control
Subjects (n) OR 95% CI
,P90 2 326 420 1
,P90 1 82 12 8.8 4.7-16.4
.P90 2 56 40 1.8 1.1-2.8
.P90 1 10 2 6.4 1.4-29.6
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variations associated with plasma TAFI levels.26 Most persons with
TAFI antigen levels exceeding the 90th percentile also have
elevated plasma levels of some other coagulation factors (Table 4).
However, none of these is responsible for the risk for thrombosis
associated with elevated TAFI levels.
Disturbances of the balance between coagulation and ﬁbrinoly-
sis may result in a bleeding disorder or in a thrombotic tendency.
In the ﬁbrinolytic pathways, both genetic defects (plasminogen
deﬁciencies and dysplasminogenemias)29,30 and abnormal labora-
tory phenotypes (increased levels of PAI-1,31 decreased levels of
t-PA32) have been reported in patients with venous thrombosis.
However, there is still serious doubt whether heterozygosity for a
plasminogen deﬁciency is associated with an increased risk for
venous thrombosis.29,30,33 Homozygous plasminogen deﬁciency
has been reported in children.34,35 Surprisingly these children suffer
from ligneous conjunctivitis and show no signs of excessive ﬁbrin
formation in the vascular compartments, indicating that plasmino-
gen-dependent ﬁbrinolysis is not important for the removal of
intravascular ﬁbrin in these children. With respect to the elevated
PAI-1 levels that have been observed in patients with venous
thrombosis,36-39 it still must be established that this is not a
postthrombotic phenomenon. On the other hand, elevated levels of
PAI-1 and t-PA antigen seem to be good markers for predicting a
second thrombotic event.32 Overall, (genetic) abnormalities in the
ﬁbrinolytic system seem not to contribute to the risk for venous
thrombosis. Excessive ﬁbrin formation seems to depend mainly on
the balance between procoagulant and anticoagulant reactions.
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